Glycos Biotechnologies Announces Successful Production of Biochemicals in Pilot Plant Size Environment
HOUSTON – (Business Wire) Glycos Biotechnologies, Inc. (GlycosBio), an emerging biochemical company pioneering metabolic engineering and microbiology innovations to produce sustainable biochemicals, today announced it has successfully produced lactic acid and advanced ethanol in a commercial size facility capable of producing up to 150,000 liters of chemicals. This is an important milestone for GlycosBio and represents a major step forward as the company works towards the worldwide commercialization of its technology.
“Replicating what has been accomplished in our lab now in a commercial setting, and at a larger scale, is a significant achievement for GlycosBio,” said Rich Cilento, Chief Executive Officer for Glycos Biotechnologies. “Our work in the pilot plant will help the organization meet partner milestones related to the commercialization efforts we already have underway. In addition, the success of the pilot production validates the efficiency and ease-of-scale of GlycosBio’s technology in larger production systems and proves our economic models and the profit opportunities we can offer producers of chemicals and biofuels. With the pilot plant successfully operational we are now focused on engaging the marketplace to secure additional commercialization partnerships around the world.”
Unlike most emerging biotechnology companies, GlycosBio has created a platform that can uniquely consume carbon from multiple non-sugar feedstock sources to produce a variety of chemical products. This approach not only eliminates the risk of a sugar-only based feedstock strategy but also provides product flexibility and a larger addressable market opportunity for producers. In addition, GlycosBio’s technology platform has been proven to be cost competitive with the petrochemical industry, while maintaining 45-55% gross margins from plant operations.
“By using our proprietary microbes and bioprocess technologies as an alternative to conventional petrochemical-based manufacturing processes, GlycosBio has invented a sustainable and cost-efficient approach to the production of next generation bio-products,” said Paul Campbell, Ph.D., Chief Scientific Officer for Glycos Biotechnologies. “Through the creation of biologically ‘balanced’ pathways inside the microbe we have been able to uniquely develop microorganisms that naturally produce the desired end-products.”
Stewards of the environment with the vision of a future in which biotechnology discoveries and process innovations create sustainable chemical alternatives, GlycosBio’s is using only microorganisms that are non-pathogenic and have been used for years to make drugs, chemicals, and enzymes for food products and detergents. GlycosBio is focused on the production of specialty chemicals that can be used as building blocks for a wide range of applications including biodegradable and non-degradable plastics. In addition, other applications for GlycosBio’s chemicals include surfactants and fuels such as advanced ethanol. By bridging innovative metabolic engineering and efficient process design, GlycosBio discoveries will drive sustainable solutions for the world’s energy, chemicals, and materials problems.
About Glycos Biotechnologies, Inc.
Glycos Biotechnologies, Inc. (GlycosBio) is an emerging biochemical company pioneering the metabolic engineering of microbial strains to consume multiple non sugar-based, low value feedstocks for the production of sustainable chemicals and advanced ethanol. By designing differentiated microorganisms, GlycosBio’s bioconversion technology lowers production cost and provides a non food energy balance savings to the chemical and biofuel industries. GlycosBio is privately held with established global relationships focused on product commercialization. For more information, visit www.glycosbio.com.
Atingo Public Relations
Suzanne Tormollen, 281-785-1280